 OncLive | Noted Researcher Offers Overview of Emerging Therapies OncLive Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer—pertuzumab (Perjeta), everolimus (Afinitor), and eribulin mesylate (Halaven)— and the progress of a promising fourth agent, ... |
